Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Barcelona Institute of Science and Technology
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | May 5, 2023
Discovery & Translation
J&J’s fusion protein for Staph infection; plus cGAS for Alzheimer’s and more
BioCentury’s roundup of translational news
BioCentury | Jan 28, 2023
Discovery & Translation
CRISPR knockdown tech from Doudna lab; plus CAR Ts for myasthenia gravis and more
BioCentury’s roundup of translational news
BioCentury | Dec 31, 2020
Distillery Therapeutics
ERR-α identified as target in diabetic and hypertensive kidney disease
DISEASE CATEGORY: Renal
INDICATION: Renal damage Promoting expression of the nuclear receptor ERR-α could treat kidney disease associated with diabetes and hypertension. Levels of ERR-α
INDICATION: Renal damage Promoting expression of the nuclear receptor ERR-α could treat kidney disease associated with diabetes and hypertension. Levels of ERR-α
BioCentury | Dec 6, 2018
Translation in Brief
Opening chromatin: long-term detriment?
Enhancing chromatin accessibility in cancer could be a liability, not a benefit
Items per page:
1 - 7 of 7